Literature DB >> 29057245

A case report of congenital glycogen storage liver cirrhosis treated with bone marrow derived stem cells.

Terek W Wehbe1, Nassim H Abi Chahine2, Abdul-Rahman A Annous3, Mohammad A Ferri4, Robert C Boulous5, Majid F El-Mestrah6.   

Abstract

Liver cirrhosis represents a state of end-stage failure that is usually fatal. The condition results in liver dysfunction, recurrent ascites, encephalopathy, renal failure, splenomegaly, bleeding, and a poor quality of life in general. With the current severe shortage of donated organs, the only available treatment in the developing countries remains palliative care. We report a case of congenital metabolic liver cirrhosis due to glycogen storage disease diagnosed at age eight. The patient, a male, received bone marrow derived mononuclear cells (BMMC) at age 16 and again at age 17 with significant improvement of his biochemical liver function tests, ascites build-up, asthenia, splenomegaly and quality of life. Furthermore, liver biopsies showed clear reduction of the inflammation and fibrosis from Ishak score dropped from 3 to 1 paralleling the symptomatic improvement of the patient.

Entities:  

Keywords:  Mononuclear stem cells; bone marrow cells; liver cirrhosis

Year:  2017        PMID: 29057245      PMCID: PMC5638994          DOI: 10.21037/sci.2017.07.04

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  21 in total

1.  Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells.

Authors:  Evangelia Yannaki; Achilles Anagnostopoulos; Demetrios Kapetanos; Angeliki Xagorari; Fotis Iordanidis; Ioannis Batsis; Panayotis Kaloyannidis; Evangelia Athanasiou; Georgios Dourvas; Georgios Kitis; Athanasios Fassas
Journal:  Exp Hematol       Date:  2006-11       Impact factor: 3.084

Review 2.  Mesenchymal stem cells in health and disease.

Authors:  Antonio Uccelli; Lorenzo Moretta; Vito Pistoia
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

3.  Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis.

Authors:  Mervat El-Ansary; Iman Abdel-Aziz; Sherif Mogawer; Samah Abdel-Hamid; Olfat Hammam; Salwa Teaema; Marwa Wahdan
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy.

Authors:  Shuji Terai; Tsuyoshi Ishikawa; Kaoru Omori; Koji Aoyama; Yoshio Marumoto; Yohei Urata; Yuichirou Yokoyama; Koichi Uchida; Takahiro Yamasaki; Yasuhiko Fujii; Kiwamu Okita; Isao Sakaida
Journal:  Stem Cells       Date:  2006-06-15       Impact factor: 6.277

5.  Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.

Authors:  Liang Peng; Dong-ying Xie; Bing-Liang Lin; Jing Liu; Hai-peng Zhu; Chan Xie; Yu-bao Zheng; Zhi-liang Gao
Journal:  Hepatology       Date:  2011-07-14       Impact factor: 17.425

Review 6.  Liver transplantation of patients in end-stage cirrhosis.

Authors:  G H Haydon; J Neuberger
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-12

Review 7.  Liver transplantation: current status and novel approaches to liver replacement.

Authors:  E B Keeffe
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

8.  Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients.

Authors:  Zheng Zhang; Hu Lin; Ming Shi; Ruonan Xu; Junliang Fu; Jiyun Lv; Liming Chen; Sa Lv; Yuanyuan Li; Shuangjie Yu; Hua Geng; Lei Jin; George K K Lau; Fu-Sheng Wang
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

9.  Therapeutic effect of autologous bone marrow-derived liver stem cells transplantation in hepatitis B virus-induced liver cirrhosis.

Authors:  XinXin Liao; Jie Yuan AnCheng; Qin Jie Zhou; CaiXian Liao
Journal:  Hepatogastroenterology       Date:  2013-05

10.  Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.

Authors:  Ming Shi; Zheng Zhang; Ruonan Xu; Hu Lin; Junliang Fu; Zhengsheng Zou; Aimin Zhang; Jianfei Shi; Liming Chen; Sa Lv; Weiping He; Hua Geng; Lei Jin; Zhenwen Liu; Fu-Sheng Wang
Journal:  Stem Cells Transl Med       Date:  2012-10-11       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.